Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 18/12/2012 18996_de.jpg

    Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie?

    Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu
  • Press release - 17/12/2012 15740_de.jpg

    Curetis AG initiates clinical trial in the U.S. towards FDA clearance

    Curetis AG announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more than 2,000 hospitalized patients suspected to have a lower respiratory tract infection and several…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-initiates-clinical-trial-in-the-u-s-towards-fda-clearance
  • Article - 03/12/2012 18832_de.jpg

    Targeted therapeutic approaches that revolutionise melanoma treatment

    Melanoma is difficult to treat once it has spread from the skin to other parts of the body. Classical chemotherapy is often ineffective and the majority of patients die within a few months after diagnosis. However, the biggest breakthrough in around 30 years has now been achieved with the development of kinase inhibitors that directly interfere with the cancer cells’ molecular signalling pathways. Clinical research into the application of kinase…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/targeted-therapeutic-approaches-that-revolutionise-melanoma-treatment
  • Press release - 12/11/2012 Immatics Logo

    immatics appoints Peter Chambré as Chairman

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-peter-chambr-as-chairman
  • Press release - 09/11/2012 Logo apogenix

    Apogenix’s Apocept™ for glioblastoma multiforme named one of “Top 10 Projects to Watch”

    Apogenix a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases announced that its lead product Apocept APG101 has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncologys Top 10 Projects To Watch.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-s-apocept-for-glioblastoma-multiforme-named-one-of-top-10-projects-to-watch
  • Press release - 30/10/2012 Logo DKFZ, blue letters "DKFZ"

    DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine

    Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
  • Article - 22/10/2012 Parametric representation of liver tissue using PIViewer®. Intensity-time curves can be produced from any image point and turned into a parameter image in off-colours (right). Here, the coding aspects of the course of the curve are represented with a freely defined fit function. The parameter image shows the differences between healthy liver tissue (top signalling curve) and metastases (bottom signalling curve) in take up of the contrast agent.

    syneed imaging: precise visualisation of functional tissue properties

    Functional medical imaging modalities are of great significance in modern medical diagnostics. Existing ways of diagnosing diseases are now being expanded with the arrival of the innovative parameter imaging method. syneed imaging uses proprietary highly sensitive software for the analysis of dynamic image data. This software complements standard methods such as computed tomography and magnetic resonance imaging and increases the significance of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/syneed-imaging-precise-visualisation-of-functional-tissue-properties
  • Article - 10/09/2012 18040_de.jpg

    Jan Wehkamp to investigate the causes of chronic inflammatory bowel diseases

    It takes a great deal of courage to question a common scientific doctrine especially for scientists at the very beginning of their careers. But around ten years ago Dr. Jan Wehkamp did not shy away from doing just that and as a result he and his scientific partner Professor Dr. Eduard Stange came up with a new explanation for the pathogenesis of chronic inflammatory bowel diseases.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/jan-wehkamp-to-investigate-the-causes-of-chronic-inflammatory-bowel-diseases
  • Press release - 08/08/2012 Logo apogenix

    Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial

    The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
  • Press release - 07/08/2012 Immatics Logo

    immatics announces publication of IMA901 cancer vaccine data in Nature Medicine

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
  • Press release - 24/07/2012 17760_de.jpg

    Tailor-made viruses for enhanced cancer therapy

    Parvoviruses specifically kill cancer cells and are already in the clinical trial stage for treating malignant brain tumors. However, as they can also infect normal cells - without doing any harm to them - a large portion of viruses is lost during therapy. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now modified parvoviruses in such a way that they initially lose their ability to infect cells. In…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-viruses-for-enhanced-cancer-therapy
  • Article - 16/04/2012 16946_de.jpg

    Pharma 2.0: towards paperless production

    Before electronic solutions existed lorries were needed to ship new drug applications which often comprised 500000 or so pages. Thanks to IT this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. Markus Roemer CEO of Ravensburg-based comes compliance services supports companies in implementing legal guidelines in this area. In the following interview Roemer talks…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/pharma-2-0-towards-paperless-production
  • Article - 20/02/2012 16506_de.jpg

    Klaus Pfizenmaier: bridging the fields between immunology and biomedicine

    Prof. Dr. Klaus Pfizenmaier has been focusing on cytokines, and in particular on the tumour necrosis factor TNF, for the last 25 years. Pfizenmaier and his team of researchers at the Institute of Cell Biology and Immunology at the University of Stuttgart have unravelled numerous facets of TNF, which is a key and versatile signalling molecule. These discoveries have led to the development of groundbreaking therapy concepts and drug candidates for…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/klaus-pfizenmaier-bridging-the-fields-between-immunology-and-biomedicine
  • Press release - 02/02/2012 Immatics Logo

    Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive
  • Article - 16/01/2012 The photo shows fifteen people standing in front of a building.

    Manfred Jung: drug discovery and the epigenetic code

    Prof. Dr. Manfred Jungs team at the University of Freiburg are chemical epigeneticists whose research involves the development of methods that enable them to identify and optimise new therapeutic drugs which are able to alter the epigenetic code of cancer and other cell types. The team use a perfidious worm for their research.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/manfred-jung-drug-discovery-and-the-epigenetic-code
  • Press release - 10/01/2012 Logo apogenix

    Apogenix receives additional 2.3 million Euros BMBF grant as partner of the biotech cluster Rhine-Neckar

    The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-receives-additional-2-3-million-euros-bmbf-grant-as-partner-of-the-biotech-cluster-rhine-ne
  • Article - 09/01/2012 16136_de.jpg

    Nutritional medicine: Can certain foods help treat cancer?

    Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
  • Press release - 09/01/2012 Logo apogenix

    Apogenix Raises 7.5 Million Euros to Further Advance APG101 to Treat Glioblastoma and other Tumors

    The biopharmaceutical company Apogenix GmbH today announced the successful completion of a € 7.5 million financing round led by dievini Hopp BioTech holding GmbH & Co. KG (dievini). Other investors include the German Cancer Research Center (DKFZ), the founders and the executive management team of Apogenix. These funds will enable Apogenix to further advance the phase II clinical trial of APG101 to treat Glioblastoma Multiforme (GBM) and other…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-raises-7-5-million-euros-to-further-advance-apg101-to-treat-glioblastoma-and-other-tumors
  • Article - 09/01/2012 16152_de.jpg

    Biomarkers to combat lung cancer

    A biomarker-driven personalised therapeutic approach to lung cancer is possible – this is the conclusion reached by the BATTLE trial. The preliminary results of the trial were summarised by scientists from the Thoraxklinik at Heidelberg University Hospital in the May 2011 issue of “Clinical Investigation”.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-to-combat-lung-cancer
  • Article - 12/12/2011 15942_de.jpg

    Rheumatoid arthritis biomarkers

    A plethora of biomarkers is available for the early diagnosis of rheumatoid arthritis and associated tissue damage and disorders. In addition, new biomarkers that improve the diagnosis and treatment of patients suffering from this common destructive autoimmune disease are constantly being discovered.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/rheumatoid-arthritis-biomarkers
  • Article - 14/11/2011 In the laboratory of BioTeSys

    BioTeSys GmbH - The basics of substance testing

    Esslingen-based BioTeSys GmbH is contracted by its clients to determine the bioactive potential of substances and substance mixtures of foods and dietary supplements. Substances are tested whether or not they have a positive effect on human health using a range of chemical analyses, cell-based tests and clinical trials.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/biotesys-gmbh-the-basics-of-substance-testing
  • Press release - 02/11/2011 15730_de.jpg

    Using Viruses to Fight Brain Tumors

    Parvoviruses can enter and kill cancer cells, but they do not cause disease in humans. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy against dangerous brain tumors that are almost impossible to treat.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/using-viruses-to-fight-brain-tumors
  • Article - 17/10/2011 15524_de.jpg

    Papillomaviruses as cancer-causing agents and how they can be fought off

    Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
  • Dossier - 05/10/2011 15491_de.jpg

    Biosimilars: follow-on biologics of innovator biopharmaceutical products

    As blockbuster biopharmaceuticals go off patent, biosimilars are increasingly competing with them for a market share. However, the production of biosimilars is rather complex and costly. The approval of biosimilars is also subject to many hurdles. Their introduction to the very expensive biopharmaceuticals market is often associated with marginal price reductions.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/biosimilars-follow-on-biologics-of-innovator-biopharmaceutical-products
  • Article - 12/09/2011 15319_de.jpg

    TransLimm brings new immunotherapies to patients more rapidly

    With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly

Page 5 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search